Media Summary: In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares some insights into the pros and cons of Mattia D'Agostino, MD, University of Turin, European Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB ...

Using Mrd To Guide Mm Treatment - Detailed Analysis & Overview

In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares some insights into the pros and cons of Mattia D'Agostino, MD, University of Turin, European Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB ... Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the ... Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, shares his views on the role of ... Jesus San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the

In this video, Caner Saygin, MD, University of Chicago, Chicago, IL, comments on Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on the Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares some insights into the dynamics of measurable residual ... Benjamin Derman, MD, University of Chicago, Chicago, IL, shares insights into the Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, comments on the potential for ... In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses how measurable residual disease (

A. Keith Stewart, MB, ChB; Sagar Lonial, MD, FACP; Edward A. Stadtmauer, MD; Amrita Krishnan, MD, FACP; Thomas Martin, MD; ... Benjamin Derman, MD, The University of Chicago, Chicago, IL, discusses measurable residual disease ( Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the Nikhil C. Munshi, MD, and Parameswaran Hari, MD, MRCP, debate the role of minimal residual disease ( Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the importance of ...

Photo Gallery

Using MRD to guide MM treatment
The benefit of using MRD to guide treatment decisions in multiple myeloma
Using MRD to guide therapy in multiple myeloma
Using MRD to Guide Therapy in AML
Using MRD to guide treatment decisions in myeloma
Positioning MRD in the myeloma treatment landscape
Using MRD to guide treatment decisions in the clinic
The importance of using MRD to guide treatment decisions in ALL
Using MRD to guide treatment decisions during SCT in multiple myeloma
Using MRD to improve prognostication during the maintenance phase of myeloma treatment
MRD-guided treatment cessation in multiple myeloma
The use of MRD to guide maintenance therapy discontinuation in patients with multiple myeloma
View Detailed Profile
Using MRD to guide MM treatment

Using MRD to guide MM treatment

Measurable residual disease (

The benefit of using MRD to guide treatment decisions in multiple myeloma

The benefit of using MRD to guide treatment decisions in multiple myeloma

In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares some insights into the pros and cons of

Using MRD to guide therapy in multiple myeloma

Using MRD to guide therapy in multiple myeloma

Mattia D'Agostino, MD, University of Turin, European

Using MRD to Guide Therapy in AML

Using MRD to Guide Therapy in AML

Harry Erba, MD, PhD, professor of medicine, director, University of Alabama (UAB) Hematologic Malignancy Program, UAB ...

Using MRD to guide treatment decisions in myeloma

Using MRD to guide treatment decisions in myeloma

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the ...

Positioning MRD in the myeloma treatment landscape

Positioning MRD in the myeloma treatment landscape

Niels van de Donk, MD, PhD, of VU University Medical Center, Amsterdam, Netherlands, shares his views on the role of ...

Using MRD to guide treatment decisions in the clinic

Using MRD to guide treatment decisions in the clinic

Jesus San Miguel, MD, Universidad de Navarra, Navarra, Spain, discusses the

The importance of using MRD to guide treatment decisions in ALL

The importance of using MRD to guide treatment decisions in ALL

In this video, Caner Saygin, MD, University of Chicago, Chicago, IL, comments on

Using MRD to guide treatment decisions during SCT in multiple myeloma

Using MRD to guide treatment decisions during SCT in multiple myeloma

Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, comments on the

Using MRD to improve prognostication during the maintenance phase of myeloma treatment

Using MRD to improve prognostication during the maintenance phase of myeloma treatment

Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, shares some insights into the dynamics of measurable residual ...

MRD-guided treatment cessation in multiple myeloma

MRD-guided treatment cessation in multiple myeloma

Benjamin Derman, MD, University of Chicago, Chicago, IL, shares insights into the

The use of MRD to guide maintenance therapy discontinuation in patients with multiple myeloma

The use of MRD to guide maintenance therapy discontinuation in patients with multiple myeloma

Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, comments on the potential for ...

Using MRD Adapted Strategy (MIDAS) to guide myeloma treatment | Sagar Lonial, MD, FACP | IMS 2024

Using MRD Adapted Strategy (MIDAS) to guide myeloma treatment | Sagar Lonial, MD, FACP | IMS 2024

Interview

Uses of MRD in patients with multiple myeloma

Uses of MRD in patients with multiple myeloma

In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses how measurable residual disease (

Using MRD to Determine Cure in Multiple Myeloma

Using MRD to Determine Cure in Multiple Myeloma

A. Keith Stewart, MB, ChB; Sagar Lonial, MD, FACP; Edward A. Stadtmauer, MD; Amrita Krishnan, MD, FACP; Thomas Martin, MD; ...

MRD in MM: Implications for clinical practice and trial design

MRD in MM: Implications for clinical practice and trial design

During the Multiple

MRD-guided therapy in multiple myeloma

MRD-guided therapy in multiple myeloma

Benjamin Derman, MD, The University of Chicago, Chicago, IL, discusses measurable residual disease (

Evaluating the use of MRD status to guide post-remission therapy in AML

Evaluating the use of MRD status to guide post-remission therapy in AML

Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the

Using MRD Status to Guide Treatment for Relapsed/Refractory Multiple Myeloma

Using MRD Status to Guide Treatment for Relapsed/Refractory Multiple Myeloma

Nikhil C. Munshi, MD, and Parameswaran Hari, MD, MRCP, debate the role of minimal residual disease (

The importance of MRD in multiple myeloma in guiding treatment decisions & access to therapies

The importance of MRD in multiple myeloma in guiding treatment decisions & access to therapies

Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the importance of ...